Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emflaza

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges patients face give them unique views on ‘value’

Bristol-Myers Squibb (BMS) building

Opdivo moves closer to head and neck cancer approval

Possible US verdict by November for BMS’ ‘breakthrough’ SCCHN therapy

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

- PMLiVE

Santhera facing long delay for muscular dystrophy drug in US

FDA rejects accelerated marketing application for Raxone to await phase II trial results

- PMLiVE

US health spending to outstrip GDP growth

New report predicts spending on healthcare will account for 20.1% of the total US economy by 2025

- PMLiVE

Blue Latitude Health expands into the US

New York City office will be led by James Atherton

- PMLiVE

Diabetes treatment ‘inextricably’ linked to patient education

Condition remains a significant burden for health systems

Shire Basingstoke

FDA finally approves Shire’s potential blockbuster Xiidra

Dry eye disease treatment wins US licence

EU flag

European pharma ‘to grow 3.2% per year by 2022’

Forecast predicts AbbVie’s Humira will be knocked off the top spot

- PMLiVE

Omnicom launches new DDB Health network

Will include its AgencyRx, Flashpoint, Synergy and DDB Health agencies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links